The National Academy of Medicine’s Dec. 12-13 meeting on the drug development paradigm in oncology was set up as a forum to discuss the move towards hyper-fast development programs, where breakthrough cancer drugs have been moving from first in human studies through to approval at record speeds.
A recurring theme across the two-day event was the need to consider the drug pricing and payment model in oncology in addressing regulatory issues. The number of times those commercial...